Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE1 | P24864 | 3/20 | 0.58 |
| ▸ | CDK2 | P24941 | 3/20 | 0.58 |
| ▸ | CDK1 | P06493 | 2/20 | 0.58 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.58 |
| ▸ | LRRK2 | Q5S007 | 7/20 | 0.45 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 4/20 | 0.42 |
| ▸ | JAK1 | P23458 | 1/20 | 0.42 |
| ▸ | JAK3 | P52333 | 1/20 | 0.42 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.42 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.42 |
| ▸ | MET | P08581 | 4/20 | 0.41 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31333791 | 0.90 | CDK1 (0.47) | CCNE1CDK2CDK1CCNB1JAK2 | |
| SCHEMBL30919647 | 0.88 | CDK1 (0.47) | CCNE1CDK2CDK1CCNB1LRRK2 | |
| SCHEMBL30919757 | 0.88 | CDK1 (0.47) | CCNE1CDK2CDK1CCNB1LRRK2 | |
| SCHEMBL30919910 | 0.86 | CDK1 (0.47) | CCNE1CDK2CDK1CCNB1LRRK2 | |
| SCHEMBL30919561 | 0.84 | CHRNB2 (0.47) | JAK2JAK1JAK3IRAK4 | |
| SCHEMBL22900922 | 0.84 | CCNE1 (0.59) | CCNE1CDK2CDK1CCNB1LRRK2 | |
| SCHEMBL30926322 | 0.83 | CDK1 (0.47) | CCNE1CDK2CDK1CCNB1FGFR1 | |
| SCHEMBL17059335 | 0.79 | KDM5B (0.48) | CCNE1CDK2CDK1CCNB1LRRK2 | |
| SCHEMBL31677603 | 0.74 | CCNE1 (0.44) | CCNE1CDK2CDK1CCNB1LRRK2 | |
| SCHEMBL22900873 | 0.74 | CCNE1 (1.00) | CCNE1CDK2CDK1CCNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210017156-A1 | PYRAZOLYL PYRIMIDINYLAMINE COMPOUNDS AS CDK2 INHIBITORS | INCYTE CORPORATION | 2021-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210017156-A1 | PYRAZOLYL PYRIMIDINYLAMINE COMPOUNDS AS CDK2 INHIBITORS | CDK2, CDK2AP2, CDK4 | CCNE1 42/4885CDK2 1/4885CDK1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.